Sanofi Dirección

Dirección controles de criterios 3/4

El CEO de Sanofi es Paul Hudson , nombrado en Sep 2019, tiene una permanencia de 5.17 años. compensación anual total es €10.57M, compuesta por 13.2% salario y 86.8% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.006% de las acciones de la empresa, por valor de $6.87M. La antigüedad media del equipo directivo y de la junta directiva es de 4.3 años y 4.6 años, respectivamente.

Información clave

Paul Hudson

Chief Executive Officer (CEO)

€10.6m

Compensación total

Porcentaje del salario del CEO	13.2%
Permanencia del CEO	5.2yrs
Participación del CEO	0.006%
Permanencia media de la dirección	4.3yrs
Promedio de permanencia en la Junta Directiva	4.6yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Paul Hudson en comparación con los beneficios de Sanofi?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	€5b
Jun 30 2024	n/a	n/a	€4b
Mar 31 2024	n/a	n/a	€5b
Dec 31 2023	€11m	€1m	€5b
Sep 30 2023	n/a	n/a	€9b
Jun 30 2023	n/a	n/a	€9b
Mar 31 2023	n/a	n/a	€8b
Dec 31 2022	€11m	€1m	€8b
Sep 30 2022	n/a	n/a	€6b
Jun 30 2022	n/a	n/a	€7b
Mar 31 2022	n/a	n/a	€7b
Dec 31 2021	€11m	€1m	€6b
Sep 30 2021	n/a	n/a	€6b
Jun 30 2021	n/a	n/a	€6b
Mar 31 2021	n/a	n/a	€12b
Dec 31 2020	€11m	€1m	€12b
Sep 30 2020	n/a	n/a	€11b
Jun 30 2020	n/a	n/a	€11b
Mar 31 2020	n/a	n/a	€3b
Dec 31 2019	€6m	€433k	€3b

Compensación vs. Mercado: La compensación total de Paul($USD11.01M) está por encima de la media de empresas de tamaño similar en el mercado UK ($USD5.69M).

Compensación vs. Ingresos: La compensación de Paul ha sido consistente con los resultados de la empresa en el último año.

CEO

Paul Hudson (57 yo)

5.2yrs

Permanencia

€10,571,822

Compensación

Mr. Paul Hudson serves as Chief Executive Officer of Sanofi at Hoechst Pakistan Limited (formerly known as sanofi-aventis Pakistan Limited). He has been Chief Executive Officer at Sanofi since September 1,...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Paul Hudson	CEO & Director	5.2yrs	€10.57m	0.0056% $ 6.9m
François-Xavier Roger	Executive VP & CFO	less than a year	sin datos	sin datos
Madeleine Roach	Executive VP & Head of Business Operations	1.1yrs	sin datos	sin datos
Laurent Gilhodes	Principal Accounting Officer and Vice President of Corporate Accounting	no data	sin datos	sin datos
Josephine Fubara	Chief Science Officer of Consumer Health Care	no data	sin datos	sin datos
Thomas Larsen	Head of Investor Relations	less than a year	sin datos	sin datos
Dante Beccaria	Global Compliance Officer & VP	12.6yrs	sin datos	sin datos
Roy Papatheodorou	Executive VP & General Counsel	2.8yrs	sin datos	sin datos
Josep Catlla	Head of Communications	no data	sin datos	sin datos
Pierre Chancel	Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing	20.3yrs	sin datos	sin datos
Natalie Bickford	Executive VP & Chief People Officer	4.3yrs	sin datos	sin datos
Marie-Hélène Laimay	Senior Vice President of Audit & Internal Control Assessment	22.5yrs	sin datos	sin datos

4.3yrs

Permanencia media

55.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 0A2V se considera experimentado (4.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Paul Hudson	CEO & Director	5.1yrs	€10.57m	0.0056% $ 6.9m
Jean-François Dehecq	Honorary Chairman	14.5yrs	€4.71m	sin datos
Serge Weinberg	Honorary Chairman	1.5yrs	€324.96k	0.00013% $ 157.8k
Patrick Kron	Independent Director	10.5yrs	€175.75k	0.000080% $ 97.1k
Lise Kingo	Independent Director	4.6yrs	€148.25k	0.000080% $ 97.1k
Frederic Oudea	Independent Chairman	1.5yrs	€573.52k	0.000080% $ 97.1k
Fabienne Lecorvaisier	Independent Director	11.5yrs	€156.50k	0.000080% $ 97.1k
Gilles Schnepp	Independent Director	2.9yrs	€175.75k	0.000080% $ 97.1k
Rachel Duan	Independent Director	4.6yrs	€145.50k	0.000080% $ 97.1k
Barbara Lavernos	Director	3.6yrs	€134.50k	0.000080% $ 97.1k
Christophe Babule	Director	5.8yrs	€134.50k	0.000080% $ 97.1k
Wolfgang Laux	Employee Representative Director	3.6yrs	€107.00k	0.00031% $ 376.4k

4.6yrs

Permanencia media

61.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 0A2V se considera experimentada (4.6 años de antigüedad promedio).

Sanofi Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Sanofi Announces Board and Committee Appointments

Recent updates

Frantz Law Group Files Oceanside Unified School District Lawsuit Against Eli Lily, Novo Nordisk, Sanofi, Express Scripts, CVS Caremark, and Optum RX for Insulin Pricing Scheme

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Review the Resubmission of the Supplemental Biologics License Application for Dupixent®?

Regeneron Pharmaceuticals, Inc. and Sanofi Receive European Union Approval For Dupixent In Young Children With Eosinophilic Esophagitis

Sanofi Announces Beyfortus (Nirsevimab) to Be Broadly Available for Babies Born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon This Fall

Sanofi Reportedly in Talks with French Government over Opella Sale

Clayton, Dubilier & Rice Reportedly Nears €15 Billion Deal for Sanofi Consumer Health Unit

Sanofi Healthcare Bidders Reportedly Revising Offers over Talc Concerns

Sanofi Reportedly Seeks Revised Proposals for Opella

Regeneron Pharmaceuticals, Inc. and Sanofi Announce National Medical Products Administration Approves Dupixent in China

Regeneron Pharmaceuticals, Inc. and Sanofi Announce National Medical Products Administration Approves Dupixent in China

Sanofi to Report Q2, 2025 Results on Jul 31, 2025

Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Approves Dupixent (Dupilumab) as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps

Sanofi Announces Tolebrutinib Meet Primary Endpoints in HERCULES Phase 3 Study

Teva Pharmaceuticals and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel Disease

Sanofi Ships U.S. Influenza Vaccines for the 2024/25 Season

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Approval in the European Union as the First-Ever Targeted Therapy for Patients with COPD

Sanofi to Present New Data from its Hemophilia Portfolio at the 32nd Congress of the International Society on Thrombosis and Haemostasis

Innate Pharma and Sanofi Shares Updated Results from the Sanofi Developed Blood Cancer Phase 1/2 1/2 SAR443579/IPH6101 Trial

Regeneron Pharmaceuticals, Inc and Sanofi Announces Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation

Sarclisa Accepts for FDA Priority Review for the Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Regeneron Pharmaceuticals, Inc. and Sanofi Presents Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in the New England Journal of Medicine

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application (sBLA) for Dupixent

Sanofi Announces Board and Committee Appointments

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad